Damjana Kastelic
Research Subjects
Research Interests
Damjana Kastelic has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Michael J. Taussig
Babraham Biosci Technol Ltd, Prot Technol Grp, Cambridge CB22 3AT, England
3 shared publications- Radovan Komel
Medical Centre for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
3 shared publications Denis Pompon
2 shared publications- Antónia Correia
University of Minho
1 shared publication - Aseel Marzoq
Division of Functional Genome Analysis, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany
1 shared publication - Birgit Schmidt
Göttingen State and University Library, University of Göttingen, Göttingen, Germany
1 shared publication
Latest Publications
- Open Access
- 19 December 2018
- Published by Ligue des Bibliotheques Europeennes de Recherche in LIBER Quarterly
- Vol. 29 (1)
A Case Report: Building communities with training and resources for Open Science trainers
- 19 December 2018
- Published by Ligue des Bibliotheques Europeennes de Recherche in LIBER Quarterly
- Vol. 29 (1)
Open AccessA Case Report: Building communities with training and resources for Open Science trainers
- Open Access
- 1 September 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1861 (9) , 2196-2205
Exploiting sequence and stability information for directing nanobody stability engineering
- 1 September 2017
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1861 (9) , 2196-2205
Open AccessExploiting sequence and stability information for directing nanobody stability engineering
- Open Access
Protein Profiling Gastric Cancer and Neighboring Control Tissues Using High-Content Antibody Microarrays
In this study, protein profiling was performed on gastric cancer tissue samples in order to identify proteins that could be utilized for an effective diagnosis of this highly heterogeneous disease and as targets for therapeutic approaches. To this end, 16 pairs of postoperative gastric adenocarcinomas and adjacent non-cancerous control tissues were analyzed on microarrays that contain 813 antibodies targeting 724 proteins. Only 17 proteins were found to be differentially regulated, with much fewer molecules than the numbers usually identified in studies comparing tumor to healthy control tissues. Insulin-like growth factor-binding protein 7 (IGFBP7), S100 calcium binding protein A9 (S100A9), interleukin-10 (IL‐10) and mucin 6 (MUC6) exhibited the most profound variations. For an evaluation of the proteins’ capacity for discriminating gastric cancer, a Receiver Operating Characteristic curve analysis was performed, yielding an accuracy (area under the curve) value of 89.2% for distinguishing tumor from non-tumorous tissue. For confirmation, immunohistological analyses were done on tissue slices prepared from another cohort of patients with gastric cancer. The utility of the 17 marker proteins, and particularly the four molecules with the highest specificity for gastric adenocarcinoma, is discussed for them to act as candidates for diagnosis, even in serum, and targets for therapeutic approaches.
Open AccessProtein Profiling Gastric Cancer and Neighboring Control Tissues Using High-Content Antibody Microarrays
In this study, protein profiling was performed on gastric cancer tissue samples in order to identify proteins that could be utilized for an effective diagnosis of this highly heterogeneous disease and as targets for therapeutic approaches. To this end, 16 pairs of postoperative gastric adenocarcinomas and adjacent non-cancerous control tissues were analyzed on microarrays that contain 813 antibodies targeting 724 proteins. Only 17 proteins were found to be differentially regulated, with much fewer molecules than the numbers usually identified in studies comparing tumor to healthy control tissues. Insulin-like growth factor-binding protein 7 (IGFBP7), S100 calcium binding protein A9 (S100A9), interleukin-10 (IL‐10) and mucin 6 (MUC6) exhibited the most profound variations. For an evaluation of the proteins’ capacity for discriminating gastric cancer, a Receiver Operating Characteristic curve analysis was performed, yielding an accuracy (area under the curve) value of 89.2% for distinguishing tumor from non-tumorous tissue. For confirmation, immunohistological analyses were done on tissue slices prepared from another cohort of patients with gastric cancer. The utility of the 17 marker proteins, and particularly the four molecules with the highest specificity for gastric adenocarcinoma, is discussed for them to act as candidates for diagnosis, even in serum, and targets for therapeutic approaches.
- 18 December 2013
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 11 (1) , 107-120
Methods for analyzing and quantifying protein–protein interaction
Genome sequencing has led to the identification of many proteins, which had not been recognized before. In consequence, the basic set of human proteins is generally known. Far less information, however, exists about protein-protein interactions, which are required and responsible for cellular activities and their control. Many protein isoforms that result from mutations, splice-variations and post-translational modifications also come into play. Until recently, interactions of only few protein partners could be analyzed in a single experiment. However, this does not meet the challenge of investigating the highly complex interaction patterns in cellular systems. It is made even more demanding by the need to determine the intensity of interactions quantitatively in order to properly understand protein interplay. Currently available techniques vary with respect to accuracy, reliability, reproducibility and throughput and their performances range from a mere qualitative demonstration of binding to a quantitative characterization of affinities. In this article, an overview is given of the methodologies available for analysis of protein-protein interactions.
- 18 December 2013
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 11 (1) , 107-120
Methods for analyzing and quantifying protein–protein interaction
Genome sequencing has led to the identification of many proteins, which had not been recognized before. In consequence, the basic set of human proteins is generally known. Far less information, however, exists about protein-protein interactions, which are required and responsible for cellular activities and their control. Many protein isoforms that result from mutations, splice-variations and post-translational modifications also come into play. Until recently, interactions of only few protein partners could be analyzed in a single experiment. However, this does not meet the challenge of investigating the highly complex interaction patterns in cellular systems. It is made even more demanding by the need to determine the intensity of interactions quantitatively in order to properly understand protein interplay. Currently available techniques vary with respect to accuracy, reliability, reproducibility and throughput and their performances range from a mere qualitative demonstration of binding to a quantitative characterization of affinities. In this article, an overview is given of the methodologies available for analysis of protein-protein interactions.
- 1 August 2013
- Published by Elsevier in Journal of Proteomics
- Vol. 88, 141-148
Optimised ‘on demand’ protein arraying from DNA by cell free expression with the ‘DNA to Protein Array’ (DAPA) technology
- 1 August 2013
- Published by Elsevier in Journal of Proteomics
- Vol. 88, 141-148
Optimised ‘on demand’ protein arraying from DNA by cell free expression with the ‘DNA to Protein Array’ (DAPA) technology
- 1 June 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1830 (6) , 3373-3381
The Global Sequence Signature algorithm unveils a structural network surrounding heavy chain CDR3 loop in Camelidae variable domains
- 1 June 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1830 (6) , 3373-3381
The Global Sequence Signature algorithm unveils a structural network surrounding heavy chain CDR3 loop in Camelidae variable domains
- 24 May 2012
- Published by Springer Nature
- Vol. 899, 61-72
Ribosome Display and Screening for Protein Therapeutics
Ribosome display is a cell-free display technology which enables in vitro selection of antibodies from large recombinant DNA libraries. It also allows continuous introduction of mutations into the selected DNA pool by PCR-based mutagenesis in each cycle, enabling selection of antibody variants with improved affinity, specificity, and stability, thus providing a powerful “protein evolution” tool for optimizing antibody therapeutics. Ribosome display selects required molecules by linking individual proteins (phenotype) with their corresponding mRNAs (genotype) through the formation of stable Protein–Ribosome–mRNA (PRM) complexes. By affinity interaction with an immobilized ligand, the captured PRM complexes are recovered as cDNA using RT-PCR from the ribosome-attached mRNA. The DNA is then subjected to subsequent ribosome display cycles for further enrichment of rare species or cloning, expression, and sequencing to identify wanted candidates. Both prokaryotic and eukaryotic cell-free systems have been developed for ribosome display of different proteins. In this chapter, we describe ribosome display of antibodies using the eukaryotic rabbit reticulocyte system with an in situ single-primer DNA recovery method. A high-throughput Escherichia coli expression format is also described for screening of individual antibody binders from the ribosome-selected population.
- 24 May 2012
- Published by Springer Nature
- Vol. 899, 61-72
Ribosome Display and Screening for Protein Therapeutics
Ribosome display is a cell-free display technology which enables in vitro selection of antibodies from large recombinant DNA libraries. It also allows continuous introduction of mutations into the selected DNA pool by PCR-based mutagenesis in each cycle, enabling selection of antibody variants with improved affinity, specificity, and stability, thus providing a powerful “protein evolution” tool for optimizing antibody therapeutics. Ribosome display selects required molecules by linking individual proteins (phenotype) with their corresponding mRNAs (genotype) through the formation of stable Protein–Ribosome–mRNA (PRM) complexes. By affinity interaction with an immobilized ligand, the captured PRM complexes are recovered as cDNA using RT-PCR from the ribosome-attached mRNA. The DNA is then subjected to subsequent ribosome display cycles for further enrichment of rare species or cloning, expression, and sequencing to identify wanted candidates. Both prokaryotic and eukaryotic cell-free systems have been developed for ribosome display of different proteins. In this chapter, we describe ribosome display of antibodies using the eukaryotic rabbit reticulocyte system with an in situ single-primer DNA recovery method. A high-throughput Escherichia coli expression format is also described for screening of individual antibody binders from the ribosome-selected population.
- 20 October 2011
- Published by Springer Nature
- Vol. 805, 75-85
Eukaryotic Ribosome Display with In Situ DNA Recovery
Ribosome display is a cell-free display technology for in vitro selection and optimisation of proteins from large diversified libraries. It operates through the formation of stable protein-ribosome-mRNA (PRM) complexes and selection of ligand-binding proteins, followed by DNA recovery from the selected genetic information. Both prokaryotic and eukaryotic ribosome display systems have been developed. In this chapter, we describe the eukaryotic rabbit reticulocyte method in which a distinct in situ single-primer RT-PCR procedure is used to recover DNA from the selected PRM complexes without the need for prior disruption of the ribosome.
- 20 October 2011
- Published by Springer Nature
- Vol. 805, 75-85
Eukaryotic Ribosome Display with In Situ DNA Recovery
Ribosome display is a cell-free display technology for in vitro selection and optimisation of proteins from large diversified libraries. It operates through the formation of stable protein-ribosome-mRNA (PRM) complexes and selection of ligand-binding proteins, followed by DNA recovery from the selected genetic information. Both prokaryotic and eukaryotic ribosome display systems have been developed. In this chapter, we describe the eukaryotic rabbit reticulocyte method in which a distinct in situ single-primer RT-PCR procedure is used to recover DNA from the selected PRM complexes without the need for prior disruption of the ribosome.
- 1 April 2011
- Published by Elsevier in New Biotechnology
- Vol. 28 (3) , 282-290
Cell free expression put on the spot: advances in repeatable protein arraying from DNA (DAPA)
- 1 April 2011
- Published by Elsevier in New Biotechnology
- Vol. 28 (3) , 282-290
Cell free expression put on the spot: advances in repeatable protein arraying from DNA (DAPA)
- 1 October 2009
- Published by Elsevier in Journal of Immunological Methods
- Vol. 350 (1-2) , 54-62
A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers
- 1 October 2009
- Published by Elsevier in Journal of Immunological Methods
- Vol. 350 (1-2) , 54-62
A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers